These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 27660339)
1. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study. Buer LC; Moum BA; Cvancarova M; Warren DJ; Medhus AW; Høivik ML J Crohns Colitis; 2017 Mar; 11(3):297-304. PubMed ID: 27660339 [TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751 [TBL] [Abstract][Full Text] [Related]
3. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population. Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793 [TBL] [Abstract][Full Text] [Related]
4. Experience with Biosimilar Infliximab (Remsima®) in Norway. Jahnsen J; Kaasen Jørgensen K Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Clinical Outcomes After Switching from Remicade Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429 [TBL] [Abstract][Full Text] [Related]
6. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease. Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037 [TBL] [Abstract][Full Text] [Related]
8. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR; Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564 [TBL] [Abstract][Full Text] [Related]
9. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. Bronswijk M; Moens A; Lenfant M; Tops S; Compernolle G; Van Assche G; Vermeire S; Gils A; Ferrante M Inflamm Bowel Dis; 2020 Mar; 26(4):628-634. PubMed ID: 31400283 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141 [TBL] [Abstract][Full Text] [Related]
11. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382 [TBL] [Abstract][Full Text] [Related]
12. Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. Plevris N; Jones GR; Jenkinson PW; Lyons M; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Din S; Shand AG; Arnott ID; Lees CW Dig Dis Sci; 2019 Jun; 64(6):1660-1667. PubMed ID: 30535885 [TBL] [Abstract][Full Text] [Related]
13. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795 [TBL] [Abstract][Full Text] [Related]
14. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330 [TBL] [Abstract][Full Text] [Related]
15. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273 [TBL] [Abstract][Full Text] [Related]
16. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Jahnsen J; Detlie TE; Vatn S; Ricanek P Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534 [TBL] [Abstract][Full Text] [Related]
17. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981 [TBL] [Abstract][Full Text] [Related]
18. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre. Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356 [TBL] [Abstract][Full Text] [Related]
19. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease. van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]